HALIFAX, England and NOVA SCOTIA, Canada, April 30 /PRNewswire/ -- ImmunoVaccine Technologies Inc. (IVT), a vaccine development company, unveiled today its DepoVax(TM) platform, a novel depot vaccine delivery system used to increase the efficacy and strength of vaccines. IVT has filed additional patents to protect the DepoVax(TM) concept.
"The results from our preclinical studies demonstrate that DepoVax(TM) is highly effective with a single dose," remarked Marc Mansour, vice president of research and development at IVT. "DepoVax(TM) is superior to conventional vaccine formulations in its ability to raise strong cellular and humoral immune responses to a variety of antigens, a hallmark of IVT's vaccine formulations."
DepoVax(TM) has been tested in pandemic influenza and therapeutic cancer models. The research shows DepoVax(TM)-vaccines deliver effective, long lasting results with only one dose.
DepoVax(TM) vaccines are readily amenable to commercialization. They can be manufactured in large batches, and are well suited for large scale distribution and long term storage. DepoVax(TM) vaccines are packaged and stored in a dry form, ensuring the stability of antigens which can otherwise be unstable in aqueous formulations. DepoVax(TM) vaccines are also easy to administer by health care practitioners, an important consideration for immunization programs targeting infectious diseases in a population.
"Our patented technology offers a dramatic boost to the effectiveness of existing vaccines," said Randal Chase, president and CEO of IVT. "An effective and easy-to-administer DepoVax(TM) vaccine would be a valuable tool for health authorities dealing with a pandemic and we are planning to take this into the clinic as soon as possible."
About IVT
ImmunoVaccine Technologies Inc. is a private, clinical-stage, vaccine development company. Through its own biotech research and collaborations with partners, IVT creates vaccines with the potential to help save and improve lives around the world.
In December 2007, IVT signed a binding MOU to acquire Pennsylvania-based Immunotope Inc. The acquisition enables IVT to create an entire pipeline of proprietary therapeutic cancer and infectious-disease specific vaccines. In January 2008, IVT licensed its technology to Pfizer Animal health, marking a pivotal step in achieving its vision of delivering breakthrough vaccines.
Contact: Brian Lowe, Vice President IVT, T: +1-902-492-1819 E: bl.ivt@immunovaccine.com Or Jennifer Ayotte, Communications, T: +1-902-209-4704 E: jayotte@impactcommunications.ca
Contact: Brian Lowe, Vice President IVT, T: +1-902-492-1819, E: bl.ivt@immunovaccine.com; Or Jennifer Ayotte, Communications, T: +1-902-209-4704, E: jayotte@impactcommunications.ca
Comments